RRA-19284 Survey of the Effectiveness of the DARZALEX® Educational Materials Regarding the Minimization of Risk of Interference for Blood Typing with Daratumumab

Study identification

• EU PAS number:
  EUPAS20119
• Study ID:
  32714
• Official title and acronym:
  RRA-19284 Survey of the Effectiveness of the DARZALEX® Educational Materials Regarding the Minimization of Risk of Interference for Blood Typing with Daratumumab
• DARWIN EU® study:
  No
• Study countries:
  Austria

  Denmark

  Finland

  France

  Germany

  Hungary

  Norway

  Slovakia

  Spain

  Sweden

  Switzerland
• Study status:
  Finalised

Study timelines

Date when funding contract was signed

Planned: 22/02/2018

Actual: 22/02/2018

Study start date

Planned: 01/09/2018

Actual: 25/09/2018

Date of final study report

Planned: 30/06/2019

Actual: 26/08/2019

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Janssen

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  EU RMP category 3 (required)